Trial · NCT00529763
Results by group141
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 141
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Major Cytogenetic Response (MCyR) | Chronic Phase (CP) CML | 50.8 | 95% Confidence Interval 37.5 to 64.1 | Percentage of participants | |
Percentage of Participants With Complete, Major, and Overall Hematologic Response (CHR, MaHR, & OHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Blast Phase CML/Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Advanced Disease CML - Accelerated Phase (AP) | CHR | 52.0 | 95% Confidence Interval 31.3 to 72.2 | Percentage of participants |
Percentage of Participants With Complete, Major, and Overall Hematologic Response (CHR, MaHR, & OHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Blast Phase CML/Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Advanced Disease CML - Blast Phase/PH+ ALL | CHR | 16.2 | 95% Confidence Interval 6.2 to 32.0 | Percentage of participants |
Percentage of Participants With Complete, Major, and Overall Hematologic Response (CHR, MaHR, & OHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Blast Phase CML/Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Advanced Disease CML - Accelerated Phase (AP) | MaHR | 84.0 | 95% Confidence Interval 63.9 to 95.5 | Percentage of participants |
Percentage of Participants With Complete, Major, and Overall Hematologic Response (CHR, MaHR, & OHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Blast Phase CML/Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Advanced Disease CML - Blast Phase/PH+ ALL | MaHR | 29.7 | 95% Confidence Interval 15.9 to 47.0 | Percentage of participants |
Percentage of Participants With Complete, Major, and Overall Hematologic Response (CHR, MaHR, & OHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Blast Phase CML/Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Advanced Disease CML - Accelerated Phase (AP) | OHR | 92.0 | 95% Confidence Interval 74.0 to 99.0 | Percentage of participants |
Percentage of Participants With Complete, Major, and Overall Hematologic Response (CHR, MaHR, & OHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Blast Phase CML/Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Advanced Disease CML - Blast Phase/PH+ ALL | OHR | 35.1 | 95% Confidence Interval 20.2 to 52.5 | Percentage of participants |
| Percentage of Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants With Complete Hematologic Response (CHR) | Chronic Phase (CP) CML | 91.5 | 95% Confidence Interval 81.3 to 97.2 | Percentage of participants | |
| Time to Major Cytogenetic Response (MCyR) in Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants | Chronic Phase (CP) CML | 12.1 | Full Range 4.3 to 48.0 | Weeks | |
| Duration of Major Cytogenetic Response (MCyR) in Chronic Phase Chronic Myeloid Leukemia (CP - CML) Participants | Chronic Phase (CP) CML | NA | 95% Confidence Interval NA to NA | Months | |
| Progression-free Survival Among CP CML Participants | Chronic Phase (CP) CML | NA | 95% Confidence Interval NA to NA | Months | |
Time to Complete and Major Hematologic Response (CHR and MaHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Participants (Ph+ ALL) | Advanced Disease CML - Accelerated Phase (AP) | CHR | 16.0 | Full Range 11.7 to 52.1 | Weeks |
Time to Complete and Major Hematologic Response (CHR and MaHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Participants (Ph+ ALL) | Advanced Disease CML - Blast Phase/PH+ ALL | CHR | 12.1 | Full Range 11.6 to 28.0 | Weeks |
Time to Complete and Major Hematologic Response (CHR and MaHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Participants (Ph+ ALL) | Total | CHR | 12.1 | Full Range 11.6 to 52.1 | Weeks |
Time to Complete and Major Hematologic Response (CHR and MaHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Participants (Ph+ ALL) | Advanced Disease CML - Accelerated Phase (AP) | MaHR | 12.1 | Full Range 11.7 to 28.6 | Weeks |
Time to Complete and Major Hematologic Response (CHR and MaHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Participants (Ph+ ALL) | Advanced Disease CML - Blast Phase/PH+ ALL | MaHR | 12.1 | Full Range 11.6 to 24.0 | Weeks |
Time to Complete and Major Hematologic Response (CHR and MaHR) in Advanced Disease Chronic Myeloid Leukemia (AD CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Participants (Ph+ ALL) | Total | MaHR | 12.1 | Full Range 11.6 to 28.6 | Weeks |
| Duration of CHR Among AD CML and Ph+ ALL Participants | Advanced Disease CML - Accelerated Phase (AP) | NA | 95% Confidence Interval 17.2 to NA | Months | |
| Duration of CHR Among AD CML and Ph+ ALL Participants | Advanced Disease CML - Blast Phase/PH+ ALL | NA | 95% Confidence Interval 13.2 to NA | Months | |
| Duration of MaHR Among AD CML and Ph+ ALL Participants | Advanced Disease CML - Accelerated Phase (AP) | NA | 95% Confidence Interval 22.9 to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00529763/results